Re: RBC unregistered to registered account
in response to
by
posted on
Apr 01, 2019 03:10AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
narmac - IMO your wish will come true but not before a royalty has started to be paid. With the info being presented this weekend on mCRPC and the start of the TNBC trial IMO Zenith Epigenetics or ZEN-3694 will not be with us to much longer. As Bear said the safety profile is darn good. 3694 will have years of testing to go before providing royalties however, apabetalone could surprise even the most progressive of thinkers as to when it will start paying royalties into ZCC if it passes the BETon MACE trial.
All IMO, dyodd
tada